MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
ONWARD MEDICAL N.V.
13 MAY 2026

Minutes of the annual general meeting of shareholders of **ONWARD Medical N.V.**, a limited liability company (*naamloze vennootschap*) incorporated under the laws of the Netherlands, having its corporate seat at Schimmelt 2-16, 5611 ZX Eindhoven, the Netherlands (the "**Company**"), held at Beethovenstraat 400, 1082 PR Amsterdam, on Wednesday, 13 May 2026 at 4:00 p.m. CEST (the "**Meeting**").

1.	*Opening*
Chair	Mr. Rob ten Hoedt, the Company's chair, acted as chair of the Meeting, opened the Meeting at 4:00 p.m. CEST, welcomed the shareholders present at the Meeting and introduced the other attendees present at the Meeting, being David L. Marver, the Company's CEO and Ali Kiboro, the Company's CFO, and several other members of the management team. Also in attendance were Lucas Buchanan and Professor Tim Denison, who were up for election this years as well as Kristina Dziekan, who was up for re-election this year. Also present was our Dutch legal counsel, Daan Hagelstein, working with NautaDutilh N.V. and the Company's auditor Hans Lemmens, working with EY Accountants B.V. Mr. Hagelstein was asked to act as secretary of the Meeting. Mr. Ten Hoedt welcomed the shareholders present at the Meeting.
Secretary	Mr. Hagelstein informed the Meeting of the following legal matters: - The Meeting has been convened with due observance of all applicable provisions of Dutch law and the Company's articles of association. - 27,690,393 shares in the Company's share capital were represented at the Meeting, representing 49.4% of the Company's issued share capital. - The requisite quorum stipulated by the Company's articles of association was represented at this Meeting. Therefore, the voting items on the agenda could be passed by simple majority. - The Meeting would be conducted in the English language.
Chair	The chair gave the floor to Mr. Marver and Mr. Kiboro.
Mr. Marver and Mr. Kiboro	Mr. Marver presented the 2025 Company highlights, including, among others, a Company overview, including an update on the technology portfolio as well as an overview of the major achievements announced in 2025. Mr. Kiboro then discussed the 2025 financial highlights of the Company. Questions were raised by Mr. Burgers on, among others, forecasts, planned sales and cost programs, as well as future capital raises and a US listing, which were answered by Mr. Marver to the satisfaction of the shareholder. Mr. Marver then gave the floor back to the chair.
Chair	The chair stated that the voting procedure for this Meeting will take place by acclamation and indicated that Mr. Hagelstein will vote in accordance with the

	voting instructions provided to him, which were already tabulated before the Meeting.
	Since there were no questions regarding the method of voting the chair proceeded to the next item on the agenda.
2.	*Discussion of the annual report over the financial year 2025 (discussion item)*
Chair	The chair indicated that the next item on the agenda is the discussion of the Company's Dutch statutory annual report over the financial year 2025, which is posted on the Company's website.
	Since there were no questions, the chair proceeded to the next item of the agenda.
3.	*Adoption of the annual accounts over the financial year 2025 (voting item)*
Chair	The chair indicated that the next agenda item is the adoption of the Company's Dutch statutory annual accounts over the financial year 2025.
	The chair indicated that the Company’s auditor is present here to address and respond to any topics raised by shareholders with respect to their audit functioning. The chair gave the word to the Company’s auditor, Hans Lemmens.
Hans Lemmens	Mr. Lemmens opened the floor for any questions the shareholders may have on the audit functioning. Given there were no questions Mr. Lemmens gave the floor back to the chair.
Chair	Since there were no further questions, the AGM voted on and passed the item.
4.	*Implementation of the compensation policy over the financial year 2025 (advisory non-binding voting item)*
Chair	The chair introduced the next agenda item, the advisory non-binding vote on the implementation of the compensation policy over the financial year 2025.
	Since there were no questions, the AGM voted on and passed the item.
5.	*Explanation of the dividend and reservation policy (discussion item)*
Chair	The chair introduced the next item on the agenda item, the discussion of the Company's dividend and reservation policy, and referred to the explanation to the agenda for further details.
	Since there were no questions, the chair proceeded to the next item on the agenda.
6.	*Release of the directors from liability for the exercise of their duties during the financial year 2025 (voting item)*
Chair	The chair introduced the following agenda item, the release of the directors from liability for the exercise of their duties during the financial year 2025.
	Since there were no questions, the AGM voted on and passed the item.
7.	*Appointment of with EY Accountants B.V. for the external audit of the Company’s annual accounts for the financial year 2026 (voting item)*
Chair	The chair introduced the following agenda item, the appointment of EY Accountants B.V. over the financial year 2026.

	Since there were no further questions, the AGM voted on the item and the vote passed.
8.	*Re-appointment of Kristina Maria Dziekan as non-executive director (voting item)*
Chair	The chair introduced the next agenda item, the re-appointment of Mrs. Kristina Maria Dziekan as non-executive director of the Company. The chair indicated that the Company believes that Mrs. Kristina Maria Dziekan highly qualified for this re-appointment given her knowledge of the Company and the dedication with which she has performed her duties as a non-executive director of the Company during her previous term of office. Since there were no questions, the AGM voted on the item and the vote passed.
9.	*Appointment of Lucas Buchanan as non-executive director (voting item)*
Chair	The chair introduced the next agenda item, the appointment of Mr. Lucas Buchanan as non-executive director of the Company. The chair indicated that the Company believes that Mr. Curtis is highly qualified for this appointment given his knowledge of the Company and the dedication with which he has performed his duties as a temporary non-executive director of the Company. Since there were no questions, the AGM voted on the item and the vote passed.
10.	*Appointment of Professor Tim Denison as non-executive director (voting item)*
Chair	The chair introduced the next agenda item, the appointment of Mr. Professor Tim Denison as non-executive director of the Company. The chair indicated that the Company believes that Mr. Professor Denison is highly qualified for this appointment given his knowledge of the Company and the dedication with which he has performed his duties as a temporary non-executive director of the Company. Since there were no further questions, the AGM voted on the item and the vote passed.
11.	*Delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the company for 10% of the company's issued share capital and to limit or exclude pre-emptive rights in connection therewith (voting item)*
Chair	The chair introduced the following item on the agenda, the delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 10% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection therewith. Since there were no questions, the AGM voted on the item and the vote passed.
12.	*Delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the company for an*

	additional 50% of the company's issued share capital and to limit or exclude pre-emptive rights in connection with a potential capital raise (voting item)
Chair	The chair introduced the following item on the agenda, the delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for an additional 50% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection with a potential capital raise. A question was raised by Mr. Burgers on the structure of the share issuance authorizations, which question was answered by Mr. Marver to the satisfaction of Mr. Burgers. Since there were no questions, the AGM voted on the item and the vote passed.
13.	*Authorization of the board to acquire ordinary shares in the Company's capital (voting item)*
Chair	The chair indicated that the next item on the agenda is the authorization of the board to acquire ordinary shares in the Company's capital. The Company proposed to renew the authorization of the board to acquire ordinary shares in the Company's capital, effectively extending the current authorization for a period ending 18 months following the date of the AGM subject to the conditions set forth in the explanatory notes to the agenda. If this resolution passed, the proposed authorization shall replace the existing authorization referred to previously. Mr. Marver responded to a question from Mr. Burgers regarding potential use of this share repurchase authorization, to the satisfaction of the shareholder. Since there were no further questions, the AGM voted on the item and the vote passed.
14. and 15.	*Questions and closing*
Chair	[***questions***] Since there were no further questions, the chair closed the Meeting at 4:32 p.m. CEST and thanked everyone for their attendance and participation.

(***signature page follows***)

Signature page to the minutes of the annual general meeting of ONWARD Medical N.V., held on 13 May 2026

_________________________	_________________________
Mr. Ten Hoedt	Mr. Hagelstein
Chair	Secretary